Jianyou Co., Ltd. announced that the ANDA application for a single dose of hydrazidrozine hydrochloride injection of its subsidiary Jianjing Pharmaceutical was approved by the US Food and Drug Administration. This drug is suitable for use in patients with severe essential hypertension when oral administration is not possible or when urgent antihypertensive relief is required. Up to now, the company has invested about 11.0597 million yuan in R&D expenses in this R&D project. The newly approved products will be listed and sold in the US in the near future, which is expected to have a positive impact on the company's operating performance.

Jianyou Co., Ltd. announced that the ANDA application for a single dose of hydrazidrozine hydrochloride injection of its subsidiary Jianjing Pharmaceutical was approved by the US Food and Drug Administration. This drug is suitable for use in patients with severe essential hypertension when oral administration is not possible or when urgent antihypertensive relief is required. Up to now, the company has invested about 11.0597 million yuan in R&D expenses in this R&D project. The newly approved products will be listed and sold in the US in the near future, which is expected to have a positive impact on the company's operating performance.